来那度胺
医学
达拉图穆马
地塞米松
内科学
多发性骨髓瘤
肿瘤科
泊马度胺
Carfilzomib公司
硼替佐米
作者
Torben Plesner,Hendrik‐Tobias Arkenau,Peter Gimsing,Jakub Krejcik,Charlotte Lemech,Monique C. Minnema,Ulrik Lassen,Jacob P. Laubach,Antonio Palumbo,Steen Lisby,Linda Basse,Jianping Wang,A. Kate Sasser,Mary Guckert,Carla de Boer,Nushmia Z. Khokhar,Howard Yeh,Pamela L. Clemens,Tahamtan Ahmadi,Henk M. Lokhorst
出处
期刊：Blood
[Elsevier BV]
日期：2016-08-17
卷期号：128 (14): 1821-1828
被引量：109
标识
DOI：10.1182/blood-2016-07-726729
摘要
Key Points Daratumumab plus lenalidomide/dexamethasone elicited an overall response rate of 81% (63% very good partial response or better). Adverse events were manageable and in accord with the individual toxicity profiles of daratumumab and lenalidomide/dexamethasone.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
cdercder
Copyright
毛豆
东方元语
无极微光
Nexus
yjh123
孤独的甜瓜
OK
zp560
Dean
arniu2008
BigTong
liuzhuohao
磷酸丙糖异构酶
初景
GingerF
学术文献互助
Zephyrite
皖公网安备34019202002308
